Kidney Transplant Rejection - Pipeline Review, H1 2017

Publisher Name :
Date: 09-May-2017
No. of pages: 148
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 9, 7, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).

  • The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Kidney Transplant Rejection - Pipeline Review, H1 2017

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 6
Global Markets Direct Report Coverage 6
Kidney Transplant Rejection - Overview 7
Kidney Transplant Rejection - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 15
Kidney Transplant Rejection - Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Kidney Transplant Rejection - Companies Involved in Therapeutics Development 24
Amgen Inc 24
Angion Biomedica Corp 24
Apellis Pharmaceuticals Inc 25
Astellas Pharma Inc 25
Biogen Inc 26
Catalyst Biosciences Inc 26
Corline Biomedical AB 27
CSL Ltd 27
GlaxoSmithKline Plc 28
Grifols SA 28
Hansa Medical AB 29
Kyowa Hakko Kirin Co Ltd 29
Magnus Life Ltd 30
Noorik Biopharmaceuticals AG 30
Novartis AG 31
Opsona Therapeutics Ltd 31
OSE Immunotherapeutics 32
Pharmicell Co Ltd 32
Pharming Group NV 33
Prolong Pharmaceuticals LLC 33
Quark Pharmaceuticals Inc 34
Shire Plc 34
Tiziana Life Sciences Plc 35
Kidney Transplant Rejection - Drug Profiles 36
albumin (human) - Drug Profile 36
ambrisentan - Drug Profile 37
AMY-101 - Drug Profile 38
APL-2 - Drug Profile 40
AS-2521780 - Drug Profile 43
ASP-0028 - Drug Profile 44
basiliximab biobetter - Drug Profile 45
BB-3 - Drug Profile 46
belimumab - Drug Profile 50
bleselumab - Drug Profile 57
C1 esterase inhibitor (human) - Drug Profile 59
C1 esterase inhibitor (human) - Drug Profile 64
C1 esterase inhibitor (recombinant) - Drug Profile 67
carfilzomib - Drug Profile 74
CB-2782 - Drug Profile 86
Cellgram for Kidney Transplant Rejection - Drug Profile 87
Cellular Immunotherapy for Kidney Transplantation - Drug Profile 88
Cellular Immunotherapy for Kidney Transplantation - Drug Profile 89
Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile 90
CFZ-533 - Drug Profile 91
foralumab - Drug Profile 93
FR-104 - Drug Profile 95
FX-06 - Drug Profile 98
GSK-1070806 - Drug Profile 100
HBI-002 - Drug Profile 101
HBI-137 - Drug Profile 102
lefluonomide - Drug Profile 103
Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 104
Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile 106
MRX-109 - Drug Profile 107
OPN-305 - Drug Profile 108
QPI-1002 - Drug Profile 111
Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile 114
Renaparin - Drug Profile 119
rituximab - Drug Profile 120
Sanguinate - Drug Profile 126
tiomolibdate diammonium - Drug Profile 129
TNT-009 - Drug Profile 130
Kidney Transplant Rejection - Dormant Projects 133
Kidney Transplant Rejection - Discontinued Products 135
Kidney Transplant Rejection - Product Development Milestones 136
Featured News & Press Releases 136
Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 145
Disclaimer 146

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Kidney Transplant Rejection - Pipeline by Amgen Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp, H1 2017
Kidney Transplant Rejection - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Biogen Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Corline Biomedical AB, H1 2017
Kidney Transplant Rejection - Pipeline by CSL Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H1 2017
Kidney Transplant Rejection - Pipeline by Grifols SA, H1 2017
Kidney Transplant Rejection - Pipeline by Hansa Medical AB, H1 2017
Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by Magnus Life Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG, H1 2017
Kidney Transplant Rejection - Pipeline by Novartis AG, H1 2017
Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by OSE Immunotherapeutics, H1 2017
Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd, H1 2017
Kidney Transplant Rejection - Pipeline by Pharming Group NV, H1 2017
Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H1 2017
Kidney Transplant Rejection - Pipeline by Shire Plc, H1 2017
Kidney Transplant Rejection - Pipeline by Tiziana Life Sciences Plc, H1 2017
Kidney Transplant Rejection - Dormant Projects, H1 2017
Kidney Transplant Rejection - Dormant Projects, H1 2017 (Contd..1), H1 2017
Kidney Transplant Rejection - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • Global Peritoneal Dialysis Solution Sales Market Report 2017
    Published: 13-Nov-2017        Price: US 4000 Onwards        Pages: 109
    In this report, the global Peritoneal Dialysis Solution market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Peritoneal Dialysis Solution for these regions, from 2012 to 2022 (forecast), covering - United States - China - ......
  • Nephrotic Syndrome - Pipeline Review, H2 2017
    Published: 07-Nov-2017        Price: US 2000 Onwards        Pages: 55
    Nephrotic Syndrome - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2017, provides an overview of the Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline landscape. Nephrotic syndrome is a kidney disorder that causes body to excrete too much protein in urine. Nephrotic syndrome is usually caused by damage to the clusters of sma......
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2017
    Published: 07-Nov-2017        Price: US 2000 Onwards        Pages: 47
    End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2017, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline landscape. End-stage kidney disease is the complete or ......
  • Chronic Kidney Disease (Chronic Renal Failure) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Chronic Kidney Disease (Chronic Renal Failure) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Chronic Kidney Disease (Chronic Renal Failure). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emer......
  • Late-stage chronic kidney disease (CKD) -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Late-stage chronic kidney disease (CKD) - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Late-stage chronic kidney disease (CKD) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Late-stage chronic kidney disease (CKD) prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden ......
  • Late-stage chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Late-stage chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Late-stage chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding ......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Acute Renal Failure (ARF) (Acute Kidney Injury) for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Acute Renal Failure (ARF) (Acute Kidney Injury) forecasted market share for ten years to......
  • Hyperoxaluria - Pipeline Insight, 2017
    Published: 01-Nov-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Hyperoxaluria-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Hyperoxaluria. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Hyperoxaluria by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a speci......
  • Lupus Nephritis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Lupus Nephritis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Lupus Nephritis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Lupus Nephritis which can turn ou......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs